TY - JOUR
T1 - Innate extracellular vesicles from melanoma patients suppress β-catenin in tumor cells by miRNA-34a
AU - Lee, Jung Hyun
AU - Dindorf, Jochen
AU - Eberhardt, Martin
AU - Lai, Xin
AU - Ostalecki, Christian
AU - Koliha, Nina
AU - Gross, Stefani
AU - Blume, Katja
AU - Bruns, Heiko
AU - Wild, Stefan
AU - Schuler, Gerold
AU - Vera, Julio
AU - Baur, Andreas S.
N1 - Publisher Copyright:
© 2019 Lee et al.
PY - 2019
Y1 - 2019
N2 - Upon tumor development, new extracellular vesicles appear in circulation. Our knowledge of their relative abundance, function, and overall impact on cancer development is still preliminary. Here, we demonstrate that plasma extracellular vesicles (pEVs) of non-tumor origin are persistently increased in untreated and post-excision melanoma patients, exhibiting strong suppressive effects on the proliferation of tumor cells. Plasma vesicle numbers, miRNAs, and protein levels were elevated two- to tenfold and detected many years after tumor resection. The vesicles revealed individual and clinical stage-specific miRNA profiles as well as active ADAM10. However, whereas pEV from patients preventing tumor relapse down-regulated β-catenin and blocked tumor cell proliferation in an miR-34a–dependent manner, pEV from metastatic patients lost this ability and stimulated β-catenin–mediated transcription. Cancer-induced pEV may constitute an innate immune mechanism suppressing tumor cell activity including that of residual cancer cells present after primary surgery.
AB - Upon tumor development, new extracellular vesicles appear in circulation. Our knowledge of their relative abundance, function, and overall impact on cancer development is still preliminary. Here, we demonstrate that plasma extracellular vesicles (pEVs) of non-tumor origin are persistently increased in untreated and post-excision melanoma patients, exhibiting strong suppressive effects on the proliferation of tumor cells. Plasma vesicle numbers, miRNAs, and protein levels were elevated two- to tenfold and detected many years after tumor resection. The vesicles revealed individual and clinical stage-specific miRNA profiles as well as active ADAM10. However, whereas pEV from patients preventing tumor relapse down-regulated β-catenin and blocked tumor cell proliferation in an miR-34a–dependent manner, pEV from metastatic patients lost this ability and stimulated β-catenin–mediated transcription. Cancer-induced pEV may constitute an innate immune mechanism suppressing tumor cell activity including that of residual cancer cells present after primary surgery.
UR - http://www.scopus.com/inward/record.url?scp=85065726247&partnerID=8YFLogxK
U2 - 10.26508/lsa.201800205
DO - 10.26508/lsa.201800205
M3 - Article
C2 - 30846484
AN - SCOPUS:85065726247
SN - 2575-1077
VL - 2
JO - Life Science Alliance
JF - Life Science Alliance
IS - 2
M1 - e201800205
ER -